Changes in18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3304-3315

  Mileshkin, Linda ^a,b   Hicks, Rodney J ^a,b   Hughes, Brett G M ^d   Mitchell, Paul L R ^b,c   Charu, Veena ^e   Gitlitz, Barbara J ^f   Macfarlane, David ^d   Solomon, Benjamin ^a   Amler, Lukas C ^g   Yu, Wei ^g   Pirzkall, Andrea ^g   Fine, Bernard M ^g  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e Pacific Cancer Medical Center   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FLUORODEOXYTHYMIDINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE; THYMIDINE;

ADULT; AGED; ARTICLE; CANCER TISSUE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; THYMIDINE;

EID: 79956021682     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2763     Document Type: Article

References (43)

1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
2. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122s-47s.
3. Tuma R. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006;98:1272-4.
4. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531-40.
5. Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 2010;16:4647-53.
6. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82. (Pubitemid 29512308)
7. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8. (Pubitemid 36793068)
8. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808. (Pubitemid 40525178)
9. Saleem A, Charnley N, Price P. Clinical molecular imaging with positron emission tomography. Eur J Cancer 2006;42:1720-7. (Pubitemid 44149089)
10. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059-66 (Pubitemid 46939960)
11. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumour imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95. (Pubitemid 46768453)
12. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181-200.
13. Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, et al. Clinical impact of 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001;19:111-8. (Pubitemid 32063487)
14. Hicks RJ. Role of FDG PET in response assessment in non-small cell lung cancer. J Nuc Med 2009;50 Suppl 1:31S-42S.
15. Shields AF. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 2003;44:1432-4. (Pubitemid 39663356)
16. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006;129:393-401. (Pubitemid 43289860)
17. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82. (Pubitemid 43073435)
18. Weber WA. Monitoring tumor response to therapy with 18F-FLT PET. J Nucl Med 2010;51:841-4.
19. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007;34:878-83. (Pubitemid 46798949)
20. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res 2007;13:6175-81. (Pubitemid 350075078)
21. Na II, Byun BH, Kang HJ, Cheon GJ, Koh JS, Kim CH, et al. 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res 2008;14:2036-41.
22. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008;59:203-10. (Pubitemid 351173409)
23. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, et al. [18F] Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-9.
24. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, et al. Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 2008;3:e3908.
25. Soto Parra H, Ippolito M, Tiseo M, Cosentino S, Ardizzoni A, Latteri F, et al. Usefulness of 18FDG-positron emission tomography (FDG-PET) for early prediction of erlotinib (Eb) treatment outcome in non-small cell lung cancer (NSCLC) patients: results of a pilot study. J Clin Oncol 2009;27:399s; abstr 7568.
26. Erlotinib (Tarceva), prescribing information. [updated 2010 Apr 19; cited 2010 Sept 9]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2010/021743s14s16lbl.pdf
27. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
28. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
29. D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:Suppl 5:v116-9.
30. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5856-8.
31. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44. (Pubitemid 41058345)
32. Zhu C-Q, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-75.
33. Herbst RS, Stern H, Amler L, Otterson G, Ling M, O'Connor P, et al. Biomarker evaluation in the Phase III, placebo-controlled, randomized BeTa trial of bevacizumab and erlotinib for patients with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes. J Thorac Oncol 2009;4:S323; abstract B2.1.
34. Paz-Ares L, Soulières D, Melezínek I, Moecks J, Keil L, Mok T, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010;14:51-69.
35. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
36. Kabbinavar F, Miller VA, Johnson BE, O'Connor PG, Soh C. Overall survival in ATLAS, a Phase IIIb trial comparing bevacizumab therapy +/-erlotinib after completion of chemotherapy with bevacizumab for first-line treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:7s; abstract 7526.
37. Binns DS, Pirzkall A, Yu W, Callahan J, Mileshkin L, Conti P, et al. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. In press 2011.
38. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature 2009;6:352-66.
39. Aukema TS, Kappers I, Olmos RA, Codrington HE, van Tinteren H, van Pel R, et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?J Nucl Med 2010;51:1344-8.
40. Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, et al. Preclinical and clinical evidence that deoxy-2-[18F]fluoro-D glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. Clin Cancer Res 2010;16:4434-45.
41. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009;15:5902-9.
42. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12:5659-67. (Pubitemid 44629592)
43. Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005;65:9633-6. (Pubitemid 41541437)